SCHEMBL7046018

SCHEMBL7046018

O=C(CCl)NCCN(CCNC(=O)CCl)CCNC(=O)CCl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
TEAD1 P28347 1/20 0.37
YAP1 P46937 1/20 0.37
TEAD4 Q15561 1/20 0.37
TEAD2 Q15562 1/20 0.37
EPHX2 P34913 1/20 0.36
DNM1 Q05193 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP3A4 P08684 1/20 0.34
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.33
FAAH O00519 2/20 0.33
TSHR P16473 2/20 0.33
ABCB11 O95342 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7402671 1.00 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL11028511 0.86 CYP1A2 (0.49) ALDH1A1SMN1; SMN2CYP1A2CYP2D6CYP3A4
SCHEMBL30649081 0.85 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2TEAD1YAP1TEAD4
Hydrochloric Acid SCHEMBL5041929 0.84 CYP3A4 (0.50) ALDH1A1SMN1; SMN2CYP1A2CYP2D6CYP3A4
SCHEMBL4461350 0.81 NPC1 (0.41) ALDH1A1SMN1; SMN2EPHX2CYP2D6KMT2A
SCHEMBL873911 0.80 DNM1 (0.55) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL5533465 0.80 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2TEAD1YAP1TEAD4
SCHEMBL29726044 0.79 CA12 (0.41) ALDH1A1SMN1; SMN2CA12CA1CA2
Hydrochloric Acid SCHEMBL1612682 0.78 DNM1 (0.53) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL11125181 0.78 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TEAD1YAP1TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010352-A1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES Belyntic GmbH (DE) 2022-06-15 EP claimed
EP-0804481-B1 SOMATOSTATIN DERIVATIVES AND THEIR RADIOLABELLED PRODUCTS DIATIDE INC (US) 2003-04-16 EP claimed
US-6056940-A TECHNETIUM-99M COMPLEXING MOIETY COVALENTLY LINKED TO A PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR BINDING MOIETY HAVING A MOLECULAR WEIGHT OF LESS THAN 10,000 DALTONS DIATIDE, INC. (US) 2000-05-02 US claimed
WO-1994023758-A1 RADIOLABELED COMPOUNDS FOR THROMBUS IMAGING DIATECH, INC. (US) 1994-10-27 WO claimed
EP-4595982-A1 MONOCONJUGATES AND THEIR PROCESS OF PREPARATION Syndivia (FR) 2025-08-06 EP disclosed
WO-2025040878-A1 COMPUTER IMPLEMENTED METHOD BICYCLETX LIMITED (GB) 2025-02-27 WO disclosed
EP-4010352-B1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES GYROS PROTEIN TECH AB (SE) 2023-10-18 EP disclosed
US-20230033370-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 BICYCLETX LIMITED (GB) 2023-02-02 US disclosed
US-20230033370-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 BICYCLETX LIMITED (GB) 2023-02-02 US disclosed
EP-4077352-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 BicycleTX Limited (GB) 2022-10-26 EP disclosed
EP-4010352-A1 A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES Belyntic GmbH (DE) 2022-06-15 EP disclosed
US-11241473-B2 Bicyclic peptide ligands and uses thereof BICYCLETX LIMITED (GB) 2022-02-08 US disclosed
US-20210046145-A1 BICYCLIC PEPTIDE LIGANDS AND USES THEREOF BICYCLETX LIMITED (GB) 2021-02-18 US disclosed
US-10857196-B2 Bicyclic peptide ligands and uses thereof BICYCLETX LIMITED (GB) 2020-12-08 US disclosed
US-10857196-B2 Bicyclic peptide ligands and uses thereof BICYCLETX LIMITED (GB) 2020-12-08 US disclosed
US-20180311300-A1 BICYCLIC PEPTIDE LIGANDS AND USES THEREOF BICYCLETX LIMITED (GB) 2018-11-01 US disclosed
EP-0772459-B1 TECHNETIUM-99m LABELED IMAGING AGENTS DIATIDE INC (US) 2003-03-19 EP disclosed
EP-0693941-B1 RADIOLABELED COMPOUNDS FOR THROMBUS IMAGING DIATIDE INC (US) 2002-07-24 EP disclosed
US-6056940-A TECHNETIUM-99M COMPLEXING MOIETY COVALENTLY LINKED TO A PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR BINDING MOIETY HAVING A MOLECULAR WEIGHT OF LESS THAN 10,000 DALTONS DIATIDE, INC. (US) 2000-05-02 US disclosed
WO-1994023758-A1 RADIOLABELED COMPOUNDS FOR THROMBUS IMAGING DIATECH, INC. (US) 1994-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10857196-B2 Bicyclic peptide ligands and uses thereof VIP, NGLY1, BID ALDH1A1 4861/4885SMN1; SMN2 4460/4885CA12 741/4885
US-20180311300-A1 BICYCLIC PEPTIDE LIGANDS AND USES THEREOF VIP, NGLY1, BID ALDH1A1 4861/4885SMN1; SMN2 4460/4885CA12 741/4885
US-20210046145-A1 BICYCLIC PEPTIDE LIGANDS AND USES THEREOF VIP, NGLY1, BID ALDH1A1 4861/4885SMN1; SMN2 4460/4885CA12 741/4885
US-20230033370-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 IL17A, IL23R, IL15 ALDH1A1 3218/4885SMN1; SMN2 4192/4885CA12 2889/4885
US-11241473-B2 Bicyclic peptide ligands and uses thereof VIP, NGLY1, BID ALDH1A1 4861/4885SMN1; SMN2 4460/4885CA12 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.